Editorials

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?

The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Texas
The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Texas
Haematologica Early view Jun 22, 2023 https://doi.org/10.3324/haematol.2023.283120